Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423518 | 0.80 | GAA (0.35) | PLK1GAAKDM4EPOLBFBP1 | |
| SCHEMBL15318256 | 0.76 | FBP1 (0.55) | BACE1FBP1 | |
| SCHEMBL19942796 | 0.76 | CTSV (0.39) | GAABACE1CTSVCTSLCTSS | |
| SCHEMBL287238 | 0.76 | ALDH1A1 (0.33) | CTSVCTSLCTSSCTSKPOLB | |
| SCHEMBL8613414 | 0.76 | IKBKB (0.38) | GAABACE1KDM4EPOLBFBP1 | |
| SCHEMBL13247707 | 0.75 | NPSR1 (0.54) | GAAKDM4EFBP1 | |
| SCHEMBL3742227 | 0.74 | POLB (0.44) | BACE1KDM4EPOLBFBP1 | |
| Hydrochloric Acid SCHEMBL19119222 | 0.74 | PDE4B (0.33) | CTSVCTSLCTSSCTSKPOLB | |
| SCHEMBL539776 | 0.74 | FBP1 (0.32) | CTSVCTSLCTSSCTSKPOLB | |
| SCHEMBL7854313 | 0.73 | GAA (0.60) | GAABACE1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329558-B2 | Method for producing compound containing heterocycle | THE UNIVERSITY OF TOKYO (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10197567-B2 | Azoline compound and azole compound library and method for producing same | THE UNIVERSITY OF TOKYO (JP) | 2019-02-05 | — | — | US | disclosed |
| US-9845326-B2 | Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-19 | — | — | US | disclosed |
| US-9840507-B2 | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, NV (BE) | 2017-12-12 | — | — | US | disclosed |
| EP-2655376-B1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-23 | — | — | EP | disclosed |
| US-9346811-B2 | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-24 | — | — | US | disclosed |
| US-9346811-B2 | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-24 | — | — | US | disclosed |
| US-20160083719-A1 | Method for Producing Compound Containing Heterocycle | THE UNIVERSITY OF TOKYO (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20140113830-A1 | Azoline Compound and Azole Compound Library and Method for Producing Same | THE UNIVERSITY OF TOKYO (JP) | 2014-04-24 | — | — | US | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PLK1 1122/4885GAA 374/4885BACE1 3601/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | PLK1 1195/4885GAA 451/4885BACE1 3452/4885 |
| US-20160083719-A1 | Method for Producing Compound Containing Heterocycle | VIP, DNPEP, PREP | PLK1 2690/4885GAA 686/4885BACE1 401/4885 |
| US-10329558-B2 | Method for producing compound containing heterocycle | VIP, DNPEP, PREP | PLK1 2690/4885GAA 686/4885BACE1 401/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | PLK1 4007/4885GAA 602/4885BACE1 3705/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | PLK1 1151/4885GAA 995/4885BACE1 3770/4885 |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | PLK1 942/4885GAA 84/4885BACE1 2/4885 |
| US-10197567-B2 | Azoline compound and azole compound library and method for producing same | PEPD, DAO, ANPEP | PLK1 2479/4885GAA 2186/4885BACE1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.